| Literature DB >> 22380592 |
Hye-Lim Ju1, Jung-Mi Kang, Sung-Ung Moon, Jung-Yeon Kim, Hyeong-Woo Lee, Khin Lin, Woon-Mok Sohn, Jin-Soo Lee, Tong-Soo Kim, Byoung-Kuk Na.
Abstract
BACKGROUND: Plasmodium vivax Duffy binding protein (PvDBP) plays an essential role in erythrocyte invasion and a potential asexual blood stage vaccine candidate antigen against P. vivax. The polymorphic nature of PvDBP, particularly amino terminal cysteine-rich region (PvDBPII), represents a major impediment to the successful design of a protective vaccine against vivax malaria. In this study, the genetic polymorphism and natural selection at PvDBPII among Myanmar P. vivax isolates were analysed.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22380592 PMCID: PMC3358247 DOI: 10.1186/1475-2875-11-60
Source DB: PubMed Journal: Malar J ISSN: 1475-2875 Impact factor: 2.979
Figure 1Sequence polymorphism of PvDBPII in . (A) Amino acid changes. Polymorphic amino acids are listed for each haplotype. Amino acids identical to those of the reference sequence, Sal I (DQ156512), are marked in yellow. The dimorphic and trimorphic amino acid changes are marked in blue and red, respectively. Total number of sequences for each haplotype is listed in right panel. (B) Frequencies of amino acid changes found in PvDBPII among Myanmar isolates.
Figure 2Phylogenetic analysis. The phylogenetic tree for the 12 haplotypes of PvDBPII was constructed with a neighbor-joining method using the MEGA4 program. Numbers on the branches indicate bootstrap proportions (1,000 replicates). Numbers on the branches indicate bootstrap proportions (1,000 replicates). The new haplotypes are marked with asterisks.
Frequencies of the most common variant amino acids in PvDBPII
| F306L | R308S | D384G | K386N | K386Q | N417K | L424I | W437R | S447K | I503K | |
|---|---|---|---|---|---|---|---|---|---|---|
| Myanmar | 7.4 | 22.2 | 85.2 | 33.3 | 5.6 | 38.9 | 83.3 | 61.1 | 0 | 77.8 |
| Thailanda | 6.7 | 26.7 | 76.7 | 40.0 | 3.0 | 36.6 | 86.7 | 63.3 | 0 | 56.7 |
| Iranb | 5.3 | 6.6 | 61.3 | 6.6 | 0 | 44.0 | 50.6 | 45.3 | 0 | 70.6 |
| Sri Lankac | 7.0 | 13.0 | 94.0 | 20.0 | 0 | 36.0 | 49.0 | 37.0 | 0 | 55.0 |
| Papua New Guinead | 0 | 67.0 | 66.0 | 8.0 | 11.0 | 23.0 | 34.0 | 26.0 | 59.0 | 29.0 |
| Colombiad | 0 | 0 | 59.0 | 23.0 | 0 | 47.0 | 47.0 | 18.0 | 0 | 12.0 |
| Brazild | 0 | 12.5 | 85.0 | 12.5 | 0 | 27.5 | 32.5 | 27.5 | 0 | 55.0 |
a [20]; b [21]; c [31]; d [19]
The first letter represents the amino acid in that position in Sal I sequence, and the other letter represents the substituted amino acid
Estimates of DNA sequence polymorphism and tests of neutrality at PvDBPII among Myanmar isolates
| Segregating sites (S) | Singleton variable sites | Parsimony informative sites | H | Hd ± SD | π ± SD | Tajima's | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 54 | 32 | 0 | 32 | 32 | 7.581 | 12 | 0.875 ± 0.029 | 0.0079 ± 0.0004 | 0.00917 | 0.00278 | 0.264 (P > 0.1) |
K, average number of pairwise nucleotide differences; H, number of haplotypes; Hd, haplotype diversity; π, observed average pairwise nucleotid diversity; Kn, rate of non-synonymous mutations; Ks, rate of synonymous mutations
Figure 3Natural selection of PvDBPII. (A) Sliding window plot of nucleotide diversity per site (π) comparing the level of genetic diversity at PvDBPII. The π values were calculated on DnaSP with window length 100 bp and step size of 25 bp. (B) The linkage disequilibrium (LD) plot showing non-random association between nucleotide variants in 54 Myanmar P. vivax isolates at different polymorphic sites. The R2 values are plotted against the nucleotide distances with two-tailed Fisher's exact test of significance.
Polymorphism observed in the each epitope sequence
| Epitope name | Epitopa | Segregating sites (S) | Singleto | Parsimony | H | Hd ± SD | π ± SD | Tajima's D | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5 | T/B | 3 | 0 | 3 | 3 | 0.565 | 4 | 0.383 ± 0.079 | 0.013 ± 0.003 | 0.016 | 0 | -0.289 (P > 0.1) |
| 13 | T | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| 16 | T/B | 1 | 0 | 1 | 1 | 0.509 | 2 | 0.509 ± 0.013 | 0.011 ± 0.000 | 0.015 | 0 | 1.741 (P > 0.05) |
| 18 | B | 1 | 0 | 1 | 1 | 0.509 | 2 | 0.509 ± 0.013 | 0.011 ± 0.000 | 0.015 | 0 | 1.741 (P > 0.05) |
| 20 | T/B | 1 | 0 | 1 | 1 | 0.509 | 2 | 0.509 ± 0.013 | 0.011 ± 0.000 | 0.014 | 0 | 1.741 (P > 0.05) |
| 28 | None | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| 40 | None | 3 | 0 | 3 | 3 | 0.867 | 3 | 0.542 ± 0.059 | 0.019 ± 0.003 | 0.018 | 0.025 | 0.642 (P > 0.1) |
| 48 | B | 5 | 0 | 5 | 5 | 1.560 | 6 | 0.748 ± 0.040 | 0.035 ± 0.003 | 0.041 | 0 | 1.007 (P > 0.1) |
| 54 | None | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| 66 | T | 1 | 0 | 1 | 1 | 0.283 | 2 | 0.283 ± 0.068 | 0.006 ± 0.002 | 0.008 | 0 | 0.382 (P > 0.1) |
| 78 | B | 1 | 0 | 1 | 1 | 0.107 | 2 | 0.107 ± 0.055 | 0.002 ± 0.001 | 0.003 | 0 | -0.675 (P > 0.1) |
| Ia | MHCIa | 3 | 0 | 3 | 3 | 0.907 | 4 | 0.649 ± 0.037 | 0.034 ± 0.004 | 0.040 | 0 | 0.767 (P > 0.1) |
| Ib | MHCIb | 2 | 0 | 2 | 2 | 0.214 | 2 | 0.107 ± 0.055 | 0.008 ± 0.004 | 0.010 | 0 | -0.898 (P > 0.1) |
| Ic | MHCIc | 2 | 0 | 2 | 2 | 0.492 | 3 | 0.458 ± 0.066 | 0.012 ± 0.002 | 0.011 | 0.017 | 0.212 (P > 0.1) |
| IIa | MHCIIa | 2 | 0 | 2 | 2 | 0.557 | 3 | 0.511 ± 0.043 | 0.019 ± 0.002 | 0.021 | 0.011 | 0.471 (P > 0.1) |
| IIb | MHCIIb | 2 | 0 | 2 | 2 | 0.423 | 3 | 0.297 ± 0.076 | 0.016 ± 0.004 | 0.019 | 0 | -0.064 (P > 0.1) |
K, average number of pairwise nucleotide differences; H, number of haplotypes; Hd, haplotype diversity; π, observed average pairwise nucleotide diversity; Kn, rate of non-synonymous mutations; Ks, rate of synonymous mutations. aB, B-cell epitope; T, T-cell epitope; none, no epitope identified